Bluemke David A, Sahani Dushyant, Amendola Marco, Balzer Thomas, Breuer Josy, Brown Jeffrey J, Casalino David D, Davis Peter L, Francis Isaac R, Krinsky Glenn, Lee Fred T, Lu David, Paulson Erik K, Schwartz Lawrence H, Siegelman Evan S, Small William C, Weber Therese M, Welber Adam, Shamsi Kohkan
Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA.
Radiology. 2005 Oct;237(1):89-98. doi: 10.1148/radiol.2371031842. Epub 2005 Aug 26.
To assess prospectively the efficacy and safety of postcontrast magnetic resonance (MR) imaging with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) compared with that of precontrast MR imaging in patients who are known to have or are suspected of having liver lesions and who are scheduled for hepatic surgery.
Investigational review board approval and written informed consent were obtained. HIPAA went into effect after data collection. A total of 172 patients were enrolled. After precontrast MR imaging, 169 patients (94 men, 75 women; mean age, 61 years; age range, 19-84 years) received an intravenous bolus of 25 micromol/kg Gd-EOB-DTPA and underwent dynamic gradient-recalled-echo and delayed MR imaging 20 minutes after injection. Arterial and portal phase computed tomography (CT) were performed within 6 weeks of MR imaging. The standard of reference was surgery with intraoperative ultrasonography (US) and biopsy and/or pathologic evaluation of resected liver segments and/or 3-month follow-up of nonresected segments if intraoperative US was not available. Three blinded reviewers and unblinded site investigators identified liver lesions on segment maps. The Wilcoxon signed rank test was used to compare differences in per-patient sensitivity of precontrast and postcontrast MR images. Adverse events were recorded, and patient monitoring and laboratory assay were performed at time of injection and up to 24 hours after contrast material administration.
At MR imaging, 316 lesions were identified in 131 patients. In 77% (P = .012), 72% (P = .15), and 71% (P = .027) of patients for readers 1, 2, and 3, respectively, more lesions were seen at precontrast and postcontrast MR imaging combined than at precontrast MR imaging alone. Sensitivity values for blinded readings were significantly greater at postcontrast MR imaging than at precontrast MR imaging for two of three blinded readers. For all blinded readers, combined precontrast and postcontrast MR images showed no difference in sensitivity compared with helical CT scans. The use of MR imaging, however, yielded fewer patients with at least one false-positive lesion (37%, 31%, and 34% of patients for readers 1, 2, and 3, respectively) than did helical CT (45%, 36%, and 43% of patients for readers 1, 2, and 3, respectively).
Compared with precontrast MR imaging, postcontrast MR imaging with Gd-EOB-DTPA demonstrated improved sensitivity for lesion detection in the majority of blinded readers, with no substantial adverse events.
前瞻性评估钆乙氧基苄基二乙三胺五乙酸(Gd-EOB-DTPA)增强磁共振(MR)成像与平扫MR成像相比,对已知或疑似有肝脏病变且计划接受肝脏手术患者的疗效和安全性。
获得研究审查委员会批准和书面知情同意书。数据收集完成后《健康保险流通与责任法案》(HIPAA)开始生效。共纳入172例患者。平扫MR成像后,169例患者(94例男性,75例女性;平均年龄61岁;年龄范围19 - 84岁)静脉注射25 μmol/kg Gd-EOB-DTPA,并于注射后20分钟行动态梯度回波和延迟MR成像。在MR成像后6周内进行动脉期和门静脉期计算机断层扫描(CT)。参考标准为手术,术中进行超声(US)检查以及对切除的肝段进行活检和/或病理评估,若无法进行术中US检查,则对未切除的肝段进行3个月随访。三名盲法阅片者和非盲法的研究点研究者在肝段图上识别肝脏病变。采用Wilcoxon符号秩检验比较平扫和增强MR图像每位患者的敏感度差异。记录不良事件,并在注射时及注射对比剂后24小时内进行患者监测和实验室检测。
MR成像时共在131例患者中发现316个病变。对于阅片者1、2和3,分别有77%(P = 0.012)、72%(P = 0.15)和71%(P = 0.027)的患者,平扫和增强MR成像联合显示的病变比单独平扫MR成像更多。对于三名盲法阅片者中的两名,增强MR成像时盲法阅片的敏感度值显著高于平扫MR成像。对于所有盲法阅片者,平扫和增强MR图像联合显示的敏感度与螺旋CT扫描相比无差异。然而,与螺旋CT(阅片者1、2和3分别为45%、36%和43%的患者)相比,MR成像时至少有一个假阳性病变的患者较少(阅片者1、2和3分别为37%、31%和34%的患者)。
与平扫MR成像相比,使用Gd-EOB-DTPA的增强MR成像在大多数盲法阅片者中对病变检测的敏感度有所提高,且无明显不良事件。